TriReme Medical, Inc. has announced that it has received FDA clearance for an expanded matrix of sizes for its unique Glider PTCA balloon catheter. Glider is now approved for the treatment of lesions in the coronary vasculature in balloon diameters from 1.5 3.5mm and in lengths from 4mm to 20mm.
TriReme describes its Glider PTCA Balloon Catheter as the world’s only torqueable angioplasty balloon catheter. It also uses words such as trackability and pushability to describe the benefits derived from its unique balloon shape and state of the art tip technology, the Glider is designed to cross through tight lesions and stent struts even in conditions where other balloons are challenged.
TriReme is clearly keen to ensure we understand that not all balloon catheters are built the same, trumpeting the unique design of its Glider which it says provides physicians with a powerful tool in managing the treatment of a broad range of complex lesions including bifurcations and tight stenoses.
TriReme Medical, Inc. is a privately held medical device company dedicated to the development, manufacturing, and commercialisation of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease.
The company is focused on the US and the emerging Asian markets.
“Glider provides interventional cardiologists with an entirely new degree of control during the treatment of complex side branches and total occlusions,” said Dr. David Rizik, Medical Director and Interventional Cardiologist at Scottsdale Heart Group in Scottsdale, AZ. “With its torqueable shaft and ultra short 4mm length, I am amazed that such a clever design can provide such powerful clinical benefits. Glider has become my ‘go-to’ balloon when I approach the treatment of my most challenging cases.”
“Our recent experience in Europe demonstrates Glider’s ability to outperform conventional ‘best in class’ balloon catheters,” said Eitan Konstantino, president and CEO of TriReme Medical, Inc. “TriReme now has three product families that have received regulatory approval in the United States. I am proud of our development team that continues to bring to market ‘out-of-the-box’ solutions to simplify complex interventional procedures.”
Source: TriReme Medical, Inc., PR Newswire